Kuo-Hsuan Hsu
Overview
Explore the profile of Kuo-Hsuan Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Wu J, Lee P, Zheng Z, Huang Y, Tseng J, Hsu K, et al.
Medicine (Baltimore)
. 2022 Jun;
101(24):e29381.
PMID: 35713442
Kirsten rat sarcoma (KRAS) mutation (KRASm) is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients. We have aimed to survey NSCLC patients harboring KRASm in Taiwan, where...
22.
Hsu K, Tseng J, Yang T, Chen K, Su K, Yu S, et al.
Sci Rep
. 2022 Jun;
12(1):9753.
PMID: 35697720
The impact of strong Programmed Death-ligand 1 (PD-L1) expression on the clinical outcomes of osimertinib in treatment naïve advanced Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) patients...
23.
Huang Y, Hsu K, Tseng J, Yang T, Chen K, Su K, et al.
Target Oncol
. 2022 Apr;
17(3):295-306.
PMID: 35460474
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with advanced and recurrent EGFR-positive non-small cell lung cancer. Objective: The main objective of the...
24.
Tseng J, Chiang C, Chen K, Zheng Z, Yang T, Lee W, et al.
JAMA Netw Open
. 2022 Mar;
5(3):e224830.
PMID: 35353165
Importance: Small cell lung carcinoma (SCLC) is uncommon in individuals who have never smoked (never-smokers). The related epidemiologic factors and prognosis remain unclear. Objective: To assess the epidemiologic factors, clinical...
25.
Huang Y, Tseng J, Hsu K, Chen K, Su K, Yu S, et al.
Sci Rep
. 2021 Aug;
11(1):17646.
PMID: 34462521
No abstract available.
26.
Lin C, Yang T, Chan M, Hsu K, Huang Y, Tseng J
J Fungi (Basel)
. 2021 Aug;
7(8).
PMID: 34436197
Pulmonary cryptococcosis in the non-human immunodeficiency virus-infected population is uncommon. We aimed to explore the relevance between clinical presentations, radiological findings, and comorbidities and identify the outcome predictors. A total...
27.
Huang Y, Hsu K, Chin C, Tseng J, Yang T, Chen K, et al.
Cancer Res Treat
. 2021 Aug;
54(2):434-444.
PMID: 34352999
Purpose: The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. Materials...
28.
Lee P, Chen K, Hsu K, Huang Y, Tseng J, Yang T, et al.
Anticancer Drugs
. 2021 Jul;
32(10):1099-1104.
PMID: 34232936
Anaplastic lymphoma kinase (ALK) translocation is a rare driver mutation in lung cancer. This study was aimed to report on the efficacy of lorlatinib in real-world practice and to evaluate...
29.
Huang Y, Tseng J, Hsu K, Chen K, Su K, Yu S, et al.
Sci Rep
. 2021 Jun;
11(1):12084.
PMID: 34103652
The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was...
30.
Huang Y, Hung J, Ko H, Su P, Lai C, Chang H, et al.
Ther Adv Med Oncol
. 2021 Jun;
13:17588359211018022.
PMID: 34093743
Background: The relative importance of predictive factors for advanced non-small cell lung cancer (NSCLC) patients on epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment remains unclear. Materials And Methods:...